Listed

Staar Surgical Co: Form 10-Q for the period ended Jun 30, 2023

Filed with the SEC on Aug 2, 2023 and accepted by EDGAR at Aug 2, 2023, 16:11 ET.

Share

Management's discussion and analysis

As filed, 23,837 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The matters addressed in this Item 2 that are not historical information constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can recognize forward-looking statements by the use of words like “anticipate,” “estimate,” “expect,” “intend,” “plan,” “believe,” “will,” “should,” “forecast” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements about any of the following: any projections of or guidance as to earnings, revenue, sales, profit margins, expense rate, cash, effective tax rate, product mix, capital expense or any other financial items; the expected impact of the COVID-19 pandemic and related public health measures (including but not limited to their impact on sales, operations or clinical trials globally), the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; statements regarding new, existing, or improved products, including but not limited to, expectations for success of new, existing, and improved products in the U.S. or international markets or government approval of a new or improved products; commercialization of new or improved products; future economic conditions or size of market opportunities; expected costs of operations; statements of belief, including as to achieving 2023 business plans; expected regulatory activities and approvals, product launches, and any statements of assumptions underlying any of the foregoing.

Although we believe that the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risks and we can give no assurance that our expectations will prove to be correct. Actual results could differ from those described in this report because of numerous factors, many of which are beyond our control. These factors include, without limitation, those described in our Annual Report on Form 10-K in “Item 1A. Risk Factors” filed on February 23, 2023. We undertake no obligation to update these forward-looking statements after the date of this report to reflect future events or circumstances or to reflect actual outcomes.

The following discussion should be read in conjunction with the audited consolidated financial statements of STAAR, including the related notes, provided in this report.

We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections. Accordingly, investors should monitor such portions of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts.

Overview

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and companion delivery systems used to deliver the lenses into the eye. We are the world’s leading manufacturer of intraocular lenses for patients seeking refractive vision correction, and we also make lenses for use in surgery to treat cataracts. All the lenses we make are foldable, which allows the surgeon to insert them into the eye through a small incision during minimally invasive surgery. Refractive surgery is performed to treat the type of visual disorders that have traditionally been corrected using eyeglasses or contact lenses. We refer to our lenses used in refractive surgery as “implantable Collamer® lenses” or “ICLs.” The field of refractive surgery includes both lens-based procedures, using products like our ICL family of products, and laser-based procedures like LASIK. Successful refractive surgery can correct common vision disorders such as myopia, hyperopia, and astigmatism. Cataract surgery is a common outpatient procedure where the eye’s natural lens that has become cloudy with age is removed and replaced with an artificial lens called an intraocular lens (“IOL”) to restore the patient’s vision. STAAR employs a commercialization strategy that strives for sustainable profitable growth. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. We position our cataract IOL lenses used in surgery that treats cataracts based on quality and value.

Recent Developments

STAAR achieved 19% growth in ICL sales in the second quarter, compared to the second quarter of 2022, with sales growth in the Asia Pacific markets up 26%, EMEA markets down 9%, and the U.S. up 10%. In China, ICL sales were up 33% compared to the second quarter of 2022. Sales in our EMEA markets were impacted by the on-going macroeconomic and geopolitical environment, as well as an inability to ship ICLs into one non-European country as a result of a country-specific product labeling change. We have taken a number of steps and implemented initiatives that we expect will accelerate EVO adoption in the U.S. as we exit 2023 and beyond. Also, we have adjusted the timing of certain marketing investments as we remain committed to prudent spending and return on our investments. Given increased conservatism related to the global environment, and slower than expected growth in the U.S, we updated our fiscal 2023 ICL sales outlook to a range of approximately $320 million to $325 million.

As part of our previously disclosed decision to wind down (i.e., no longer manufacture and reduce support) our Other Products business (i.e., our low margin cataract IOLs and related delivery systems), we decided to take additional sales return and inventory reserves for our remaining Other Products business. This included a $0.7 million sales return reserve for expected returns of our acrylic IOLs; $1.2 million inventory reserve for acrylic IOLs; and $1.6 million inventory reserve for silicone IOLs. As previously disclosed, in March 2023 we issued a Field Safety Notice to affected customers in parts of Europe and Japan to stop using our acrylic cataract IOLs. This was done as a precautionary measure in response to a Field Safety Notice issued by another company regarding a similarly manufactured product. To date, testing of our acrylic cataract IOL and injector system has been inconclusive and has not identified a root cause that would result in a safety issue. Nevertheless, in an abundance of caution, STAAR Japan has asked clinics to no longer use the acrylic IOL system and return them for a credit.

Critical Accounting Estimates

This Management’s Discussion and Analysis of Financial Condition and Results of Income discusses and analyzes data in our unaudited Condensed Consolidated Financial Statements provided in this report, which we have prepared in accordance with U.S. generally accepted accounting principles. Preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual conditions may differ from our assumptions and actual results may differ from our estimates.

Management believes that there have been no significant changes during the six months ended June 30, 2023 to the items that we disclosed as our critical accounting estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 30, 2022.

Results of Operations

The following table shows the percentage of our total sales represented by certain items reflected in our Condensed Consolidated Statements of Income for the periods indicated.

Percentage of Net Sales for Three Months June 30, 2023 July 1, 2022 Percentage of Net Sales for Six Months June 30, 2023 July 1, 2022
Net sales 100.0% 100.0% 100.0% 100.0%
Cost of sales 23.4% 21.2% 22.6% 21.6%
Gross profit 76.6% 78.8% 77.4% 78.4%
General and administrative 19.6% 17.2% 21.8% 18.0%
Selling and marketing 35.0% 29.9% 35.4% 28.8%
Research and development 12.7% 10.7% 13.3% 11.4%
Total selling, general and administrative 67.3% 57.8% 70.5% 58.2%
Operating income 9.3% 21.0% 6.9% 20.2%
Total other income (expense), net (0.1)% (1.9)% 1.1% (1.5)%
Income before income taxes 9.2% 19.1% 8.0% 18.7%
Provision for income taxes 2.6% 3.0% 2.7% 3.0%
Net income 6.6% 16.1% 5.3% 15.7%

18

Net Sales

The following table presents our net sales, by product (dollars in thousands):

Three Months Ended June 30, 2023 July 1, 2022 Percentage Change 2023 vs. 2022 Six Months Ended June 30, 2023 July 1, 2022 Percentage Change 2023 vs. 2022
ICLs $93,112 $77,922 19.5% $163,737 $136,597 19.9%
Other product sales:
Cataract IOLs 40 2,547 (98.4)% 1,516 5,449 (72.2)%
Other surgical products (846) 632 — * 581 2,255 (74.2)%
Total other product sales (806) 3,179 — * 2,097 7,704 (72.8)%
Net sales $92,306 $81,101 13.8% $165,834 $144,301 14.9%

* Denotes change is greater than +100%.

Net sales for the three months ended June 30, 2023 increased 14% from the same period of 2022. The increase in net sales was primarily due to increased ICL sales of $15.2 million, slightly offset by decreased other product sales of $4.0 million. Changes in foreign currency unfavorably impacted net sales by $0.4 million.

Net sales for the six months ended June 30, 2023 increased 15% from the same period of 2022. The increase in net sales was primarily due to increased ICL sales of $27.1 million, slightly offset by decreased other product sales of $5.6 million. Changes in foreign currency unfavorably impacted net sales by $2.4 million.

Total ICL sales for the three months ended June 30, 2023 increased 19% from the same period of 2022, with unit increase of 21%. The APAC region sales increased by 26%, with unit growth up 29%, due to sales growth in China up 33%, India up 14% and Japan up 13%, partially offset by sales decreases in Korea down 15%. The Europe, Middle East, Africa and Latin America region sales decreased 9% with unit decrease of 23%, due to sales decreases in our distributor markets down 14% and direct markets down 4%. The North America region sales increased 10%, with unit growth up 10%, primarily due to sales growth in the U.S. up 10%. Changes in foreign currency unfavorably impacted ICL sales by $0.4 million for the three months ended June 30, 2023, which impacted our Japan and Europe, Middle East and Africa markets. ICL sales represented 100.9% and 96.1% of our total sales for the three months ended June 30, 2023 and July 1, 2022, respectively.

Total ICL sales for the six months ended June 30, 2023 increased 20% from the same period of 2022, with unit increase of 21%. The APAC region sales increased by 23%, with unit growth up 25%, due to sales growth in China up 30%, other APAC regions up 13%, India up 11%, Japan up 9% and Korea up 5%. The Europe, Middle East, Africa and Latin America region sales were flat with unit decrease of 7%, due to sales decreases in our distributor markets down 1%, offset by growth in in our direct markets up 1%. The North America region sales increased 29%, with unit growth up 30%, primarily due to sales growth in the U.S. up 34%. In late March 2022, the U.S. started to sell EVO ICLs. Changes in foreign currency unfavorably impacted ICL sales by $2.1 million for the six months ended June 30, 2023, which impacted our Japan and Europe, Middle East and Africa markets. ICL sales represented 98.7% and 94.7% of our total sales for the six months ended June 30, 2023 and July 1, 2022, respectively.

Other product sales, includes cataract IOLs, delivery systems and normal recurring sales adjustments such as sales return allowances. As a result of third-party materials and supply chain challenges that affect our cataract IOLs and associated delivery devices, we will no longer manufacture cataract IOLs, though we will continue to support these products through the end of 2023, as supplies permit. We do not expect this decision to have a significant impact to revenue growth in future years. Other product sales for the three and six months ended June 30, 2023, decreased 125% and 73%, respectively, from the same period of 2022, due to primarily to a reduction in cataract IOL sales, decreased sales of cataract IOL injector parts and sales return reserves related to cataract IOLs. Changes in foreign currency unfavorably impacted other product sales by $0.3 million for the six months ended June 30, 2023. Other product sales represented (0.9%) and 3.9% of our total sales for the three months ended June 30, 2023 and July 1, 2022, respectively, and represented 1.3% and 5.3% of our total sales for the six months ended June 30, 2023 and July 1, 2022, respectively.

Gross Profit

The following table presents our gross profit and gross profit margin (dollars in thousands):

Three Months Ended June 30, 2023 July 1, 2022 Percentage Change 2023 vs. 2022 Six Months Ended June 30, 2023 July 1, 2022 Percentage Change 2023 vs. 2022
Gross profit $70,726 $63,872 10.7% $128,288 $113,136 13.4%
Gross margin 76.6% 78.8% 77.4% 78.4%

Gross profit for the three and six months ended June 30, 2023 increased 10.7% and 13.4%, respectively, from the same periods of 2022. Gross profit margin decreased to 76.6% and 77.4% of revenue for the three and six months ended June 30, 2023, respectively, compared to 78.8% and 78.4% of revenue for the three and six months ended July 1, 2022, respectively, due mainly to reserves related to cataract IOLs.

General and Administrative Expense

The following table presents our general and administrative expenses (dollars in thousands):

Three Months Ended June 30, 2023 July 1, 2022 Percentage Change 2023 vs. 2022 Six Months Ended June 30, 2023 July 1, 2022 Percentage Change 2023 vs. 2022
General and administrative expense $18,097 $13,983 29.4% $36,195 $25,923 39.6%
Percentage of sales 19.6% 17.2% 21.8% 18.0%

General and administrative expenses for the three months ended June 30, 2023 increased 29.4% from the same period of 2022 due to increased salary-related and payroll tax expenses, outside services and facility costs.

General and administrative expenses for the six months ended June 30, 2023 increased 39.6% from the same period of 2022 due to increased bonus and stock-based compensation expenses, salary-related and payroll tax expenses, Japan one-time employee benefits, outside services, and facility costs.

Selling and Marketing Expense

The following table presents our selling and marketing expenses (dollars in thousands):

Three Months Ended June 30, 2023 July 1, 2022 Percentage Change 2023 vs. 2022 Six Months Ended June 30, 2023 July 1, 2022 Percentage Change 2023 vs. 2022
Selling and marketing expense $32,277 $24,233 33.2% $58,631 $41,503 41.3%
Percentage of sales 35.0% 29.9% 35.4% 28.8%

Selling and marketing expenses for the three months ended June 30, 2023 increased 33.2% from the same period of 2022 due to increased advertising and promotional activities, especially in the U.S., salary-related and payroll tax expenses, bonus and stock-based compensation expenses, sales commission expenses and trade shows and sales meetings expenses.

Selling and marketing expenses for the six months ended June 30, 2023 increased 41.3% from the same period of 2022 due to increased advertising and promotional activities, especially in the U.S., salary-related and payroll tax expenses, sales commission expenses, trade shows and sales meetings expenses and bonus and stock-based compensation expenses.

Research and Development Expense

The following table presents our research and development expenses (dollars in thousands):

Three Months Ended June 30, 2023 July 1, 2022 Percentage Change 2023 vs. 2022 Six Months Ended June 30, 2023 July 1, 2022 Percentage Change 2023 vs. 2022
Research and development expense $11,755 $8,636 36.1% $22,065 $16,577 33.1%
Percentage of sales 12.7% 10.7% 13.3% 11.4%

Research and development expenses for the three and six months ended June 30, 2023 increased 36.1% and 33.1% from the same period of 2022, respectively, due mainly to increased salary-related and payroll tax expenses and clinical expenses associated with our U.S. post-approval clinical trials, and for the six months ended June 30, 2023, increased bonus and stock-based compensation expenses as compared to the six months ended July 1, 2022.

Other Expense, Net

The following table presents our other expenses, net (dollars in thousands):

Three Months Ended June 30, 2023 July 1, 2022 Percentage Change 2023 vs. 2022 Six Months Ended June 30, 2023 July 1, 2022 Percentage Change 2023 vs. 2022
Other income (expense), net $(105) $(1,551) 93.2% $1,814 $(2,137) — *
Percentage of sales (0.1)% (1.9)% 1.1% (1.5)%

* Denotes change is greater than +100%.

The change in other income (expense), net for the three and six months ended June 30, 2023 and July 1, 2022, respectively, was due to increased interest income mainly due to our investments held available for sale and for the six months ended June 30, 2023 lower foreign exchange losses as compared to the six months ended July 1, 2022.

Income Taxes

The following table presents our income tax provision (dollars in thousands):

Three Months Ended June 30, 2023 July 1, 2022 Percentage Change 2023 vs. 2022 Six Months Ended June 30, 2023 July 1, 2022 Percentage Change 2023 vs. 2022
Income tax provision $2,428 $2,431 (0.1)% $4,437 $4,356 1.9%

The effective tax rates for the three months ended June 30, 2023 and July 1, 2022 were 28.6% and 15.7%, respectively, and were 33.6% and 16.1% for the six months ended June 30, 2023 and July 1, 2022, respectively. Our effective tax rates differ from the U.S. federal statutory rate of 21%, primarily due to the income tax expense generated in foreign jurisdictions.

Our future effective income tax rate depends on various factors, such as changes in tax laws, regulations, accounting principles, or interpretations thereof, and the geographic composition of our pre-tax income. We carefully monitor these factors and adjust our effective income tax rate accordingly.

Liquidity and Capital Resources

We believe that current cash and cash equivalents, investments available for sale (“AFS”) and future cash flow from operating activities will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the financial statements included in this quarterly report. Our financial condition at June 30, 2023 and December 30, 2022 included the following (in thousands):

June 30, 2023 December 30, 2022 2023 vs. 2022
Cash and cash equivalents $94,695 $86,480 $8,215
Investments available for sale 114,837 139,061 (24,224)
Total $209,532 $225,541 $(16,009)
Current assets $328,003 $311,723 $16,280
Current liabilities 54,194 51,716 2,478
Working capital $273,809 $260,007 $13,802

Cash and cash equivalents include cash and balances in deposits and money market accounts held at banks and financial institutions. Our investment policy primary objective is capital preservation while maximizing our return on investment. Investments available for sale may include U.S. government and corporate debt securities, commercial paper, certain certificates deposit and related security types, that are rated by two nationally recognized statistical rating organizations with minimum investment grade ratings of AAA to A-/A-1+ to A-2, or the equivalent. The maturity of individual investments may not extend 24 months from the date of purchase. There are also limits to the amount of credit exposure in any given security type. We do not have any off-balance sheet arrangements.

A summary of cash flows for the six months ended June 30, 2023 and July 1, 2022 was as follows (in thousands):

Cash flows from: Six Months Ended June 30, 2023 July 1, 2022
Operating activities $(11,400) $8,636
Investing activities 20,105 (7,810)
Financing activities (59) 3,101
Effect of exchange rate changes (431) (1,143)
Net increase in cash and cash equivalents 8,215 2,784
Cash and cash equivalents, at beginning of year 86,480 199,706
Cash and cash equivalents, at end of year $94,695 $202,490

For the six months ended June 30, 2023 net cash used by operating activities consisted of $39.5 million in working-capital changes partially offset by $19.3 million in non-cash items and net income of $8.8 million.

Starting in the second half of 2022, we decided to invest our cash in slightly higher yielding securities. For the six months ended June 30, 2023, net cash provided by investment activities was $20.1 million which consisted of $68.6 million of proceeds from the sale or maturity of investments AFS, partially offset by $42.6 million in purchases of investments AFS and $5.9 million in purchases of property, plant and equipment. For the six months ended July 1, 2022, net cash used in investment activity consisted of $7.8 million in purchases of property, plant and equipment.

Net cash used in financing activities for the six months ended June 30, 2023 was $0.1 million which consisted of $2.0 million to repurchase of employee common stock for taxes withheld and $0.1 million to repay finance lease obligations, offset by $2.0 million of proceeds from the exercise of stock options. For the six months ended July 1, 2022, net cash provided by financing activities consisted of $3.1 million of proceeds from the exercise of stock options.

Commitments

Employment Agreements

The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective January 1, 2023. He and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all of its assets, or termination “without cause or for good reason” as defined in the employment agreements.

Market risk

As filed, 239 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

During the six months ended June 30, 2023, there have been no material changes in the Company’s qualitative and quantitative market risk since the disclosure in the Company’s Annual Report on Form 10-K for the year ended December 30, 2022.

Controls and procedures

As filed, 3,361 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of the design and operation of the disclosure controls and procedures of the Company. Based on that evaluation, our CEO and CFO concluded, as of the end of the period covered by this quarterly report on Form 10-Q, that our disclosure controls and procedures were effective. For purposes of this statement, the term “disclosure controls and procedures” means controls and other procedures of the Company that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management, including the CEO and the CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud or material errors. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations on all internal control systems, our internal control system can provide only reasonable assurance of achieving its objectives and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of internal control is also based in part upon certain assumptions about the likelihood of future events, and can provide only reasonable, not absolute, assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in circumstances, or the degree of compliance with the policies and procedures may deteriorate.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 452 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our short and long-term success is subject to many factors that are beyond our control. Investors and prospective investors should consider carefully information contained in this report and the risks and uncertainties described in “Part I—Item 1A—Risk Factors” of the Company’s Form 10-K for the fiscal year ended December 30, 2022. Such risks and uncertainties could materially adversely affect our business, financial condition or operating results.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-04-01 to 2023-06-30$92.3mus-gaap:Revenues
Revenue6 months2022-12-31 to 2023-06-30$165.8mus-gaap:Revenues
Cost of revenue3 months2023-04-01 to 2023-06-30$21.6mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2022-12-31 to 2023-06-30$37.5mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2023-04-01 to 2023-06-30$70.7mus-gaap:GrossProfit
Gross profit6 months2022-12-31 to 2023-06-30$128.3mus-gaap:GrossProfit
Research and development3 months2023-04-01 to 2023-06-30$11.8mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2022-12-31 to 2023-06-30$22.1mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2023-04-01 to 2023-06-30$62.1mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2022-12-31 to 2023-06-30$116.9mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2023-04-01 to 2023-06-30$8.6mus-gaap:OperatingIncomeLoss
Operating income6 months2022-12-31 to 2023-06-30$11.4mus-gaap:OperatingIncomeLoss
Income tax3 months2023-04-01 to 2023-06-30$2.4mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2022-12-31 to 2023-06-30$4.4mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-04-01 to 2023-06-30$6.1mus-gaap:NetIncomeLoss
Net income6 months2022-12-31 to 2023-06-30$8.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-04-01 to 2023-06-30$0.12us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2022-12-31 to 2023-06-30$0.18us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-04-01 to 2023-06-30$0.13us-gaap:EarningsPerShareBasic
Basic EPS6 months2022-12-31 to 2023-06-30$0.18us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-04-01 to 2023-06-3049,516,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2022-12-31 to 2023-06-3049,524,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2022-12-31 to 2023-06-30−$11.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2022-12-31 to 2023-06-30$5.9mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2023-06-30$94.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-06-30$328.0mus-gaap:AssetsCurrent
Total assetsAt period end2023-06-30$440.7mus-gaap:Assets
Current liabilitiesAt period end2023-06-30$54.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-06-30$87.0mus-gaap:Liabilities
Shareholders' equityAt period end2023-06-30$353.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-23-037163. Last ingested by Listed: Nov 4, 2026, 17:00 ET. Listed shows no prices and gives no investment advice.